16 Apr 2026 · 3 min read
OpenAI in pharma: Novo Nordisk, GPT-Rosalind, and the life sciences platform play
Last week, OpenAI made two moves in pharma within 48 hours — a flagship enterprise deal with Novo Nordisk and the launch of GPT-Rosalind — and the sequencing tells a deliberate story about how they're building a verticalised commercial infrastructure for life sciences. Having sat on the pharma buyer side, I break down what that cadence actually accomplishes.